By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Resverlogix Corporation 

4820 Richard Road SW
Suite 300
Calgary  Alberta  T3E 6L1  Canada
Phone: 403-254-9252 Fax: 403-256-8495


SEARCH JOBS








Company News
Resverlogix (RVX.TO) Reports Positive FDA Type B Meeting On Design Issues Relating To A Proposed Phase IIa Kidney Dialysis Trial 2/23/2017 7:32:35 AM
Resverlogix (RVX.TO) Highlights Unique Properties Of Apabetalone In Both A Rare Muscular Dystrophy (FSHD) And Neurodegenerative Eye Disease 2/13/2017 6:51:13 AM
Resverlogix (RVX.TO) Release: Company Provides Groundbreaking Results In Patients With Severe Kidney Impairments 1/23/2017 10:05:43 AM
Resverlogix (RVX.TO) Announces Voting Results From The 2016 Annual And Special Meeting Of Shareholders 12/16/2016 9:50:54 AM
Resverlogix (RVX.TO) Announces Filing Of Quarterly Financial Statements And Management's Discussion & Analysis 12/14/2016 9:45:15 AM
Resverlogix (RVX.TO) Announces Second Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study Of Apabetalone (RVX-208) 12/6/2016 6:45:00 AM
Resverlogix (RVX.TO) Announces Successful Phase 1 Renal Trial Results: Clears Path For Future Phase 2 Studies 11/17/2016 8:04:45 AM
Resverlogix (RVX.TO) Announces Annual And Special Meeting Of Shareholders 10/7/2016 6:58:13 AM
Resverlogix (RVX.TO) To Host Research & Development Update Featuring Key Opinion Leaders In Cardiovascular And Renal Disease 10/4/2016 9:30:17 AM
Resverlogix (RVX.TO) Announces Filing Of Quarterly Financial Statements And Management's Discussion & Analysis 9/15/2016 10:46:11 AM
12345678910...
//-->